Retatrutide: difference between revisions
Diff·revision 5 → 6·09:36, 7 Aug 2024
Difference between revision 5 and revision 6 of Retatrutide. 2 lines changed; the page grew by 278 bytes.
| Revision 5 — 15:20, 29 Jul 2024 FmocFrancis (talk) fix indentation in the source 2,444 bytes ±0 | Revision 6 — 09:36, 7 Aug 2024 EscalationEira (talk) reorder the analogues chronologically rather than alphabetically 2,722 bytes +278 | ||
|---|---|---|---|
| 16 | Reported ''in vitro'' potencies place the molecule closest to native ligand at the GIP receptor, with somewhat lower relative activity at the GLP-1 and glucagon receptors. These ratios are assay-dependent and should be compared only within a single publication's system; cross-publication comparison of receptor ratios is a common error in secondary sources. | 16 | Reported ''in vitro'' potencies place the molecule closest to native ligand at the GIP receptor, with somewhat lower relative activity at the GLP-1 and glucagon receptors. These ratios are assay-dependent and should be compared only within a single publication's system; cross-publication comparison of receptor ratios is a common error in secondary sources. |
| 17 | 17 | ||
| + | 18 | Half-life extension uses the established combination of a protease-resistant residue near the N-terminus and a fatty diacid for [[Albumin binding half-life extension|albumin binding]], giving a reported half-life of about six days and supporting weekly dosing.{{r|coskun2022}} | |
| + | 19 | ||
| 18 | == References == | 20 | == References == |
| 19 | {{reflist}} | 21 | {{reflist}} |